A safety and efficacy study of CTX001 in transfusion-dependent patients with ß-Thalassemia
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs CTX 001 (Primary)
- Indications Beta-thalassaemia
- Focus Therapeutic Use
- Sponsors CRISPR Therapeutics
- 07 Dec 2017 According to a CRISPR Therapeutics media release, the company has submitted a Clinical Trial Application (CTA) to conduct this trial.
- 15 Nov 2017 New trial record
- 08 Nov 2017 According to a CRISPR Therapeutics media release, the company will filed CTA package filed by year-end 2017 to begin this trial in 2018.